[A24-42] Etrasimod (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V
Last updated 15.07.2024
Project no.:
A24-42
Commission:
Commission awarded on 15.04.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Indication:
Adults and adolescents 16 years of age and older with moderately to severely active ulcerative colitis
Result of dossier assessment:
- Patients who have had an inadequate response, lost response, or were intolerant to conventional therapy: added benefit not proven
- Patients who have had an inadequate response, lost response, or were intolerant to a biological agent: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-42_en